• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制 AKT 信号通路通过同源介导的 DNA 修复靶向作用使软组织肉瘤(STS)和胃肠道间质瘤(GIST)对多柔比星敏感。

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair.

机构信息

Department of Pathology, Kazan State Medical University, 420012 Kazan, Russia.

Central Research Laboratory, Kazan State Medical University, 420012 Kazan, Russia.

出版信息

Int J Mol Sci. 2020 Nov 22;21(22):8842. doi: 10.3390/ijms21228842.

DOI:10.3390/ijms21228842
PMID:33266502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7700672/
Abstract

Activation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is well documented for a broad spectrum of human malignancies supporting their growth and progression. Accumulating evidence has also implicated AKT as a potent modulator of anti-cancer therapies via regulation of DNA damage response and repair (DDR) induced by certain chemotherapeutic agents and ionizing radiation (IR). In the present study, we examined the role of AKT signaling in regulating of Rad51 turnover and cytotoxic effects of topoisomerase II inhibitor, doxorubicin (Dox) in soft tissue sarcomas (STS) and gastrointestinal stromal tumors (GIST) in vitro. Blocking of AKT signaling (MK-2206) enhanced cytotoxic and pro-apoptotic effects of Dox in vast majority of STS and GIST cell lines. The phosphorylated form of Akt co-immunoprecipitates with Rad51 after Dox-induced DNA damage, whereas Akt inhibition interrupts this interaction and decreases Rad51 protein level by enhancing protein instability via proteasome-dependent degradation. Inhibition of Akt signaling in Dox-treated cells was associated with the increased number of γ-H2AX-positive cells, decrease of Rad51 foci formation and its colocalization with γ-H2AX foci, thereby revealing unsuccessful DDR events. This was also in consistency with an increase of tail moment (TM) and olive tail moment (OTM) in Dox-treated GIST and STS cells cultured in presence of Akt inhibitor after Dox washout. Altogether, our data illustrates that inhibition of AKT signaling is STS and GIST might potentiate the cytotoxic effect of topoisomerase II inhibitors via attenuating the homology-mediated DNA repair.

摘要

磷酸肌醇 3-激酶(PI3K)/Akt/mTOR 途径的激活在广泛的人类恶性肿瘤中得到了充分的证实,支持它们的生长和进展。越来越多的证据也表明,AKT 通过调节某些化疗药物和电离辐射(IR)诱导的 DNA 损伤反应和修复(DDR),成为抗癌治疗的有效调节剂。在本研究中,我们研究了 AKT 信号在调节拓扑异构酶 II 抑制剂阿霉素(Dox)在软组织肉瘤(STS)和胃肠道间质瘤(GIST)中的 Rad51 周转率和细胞毒性作用中的作用。阻断 AKT 信号(MK-2206)增强了绝大多数 STS 和 GIST 细胞系中 Dox 的细胞毒性和促凋亡作用。Dox 诱导 DNA 损伤后,磷酸化形式的 Akt 与 Rad51 共免疫沉淀,而 Akt 抑制通过增强蛋白酶体依赖性降解来中断这种相互作用并降低 Rad51 蛋白水平。在 Dox 处理的细胞中抑制 Akt 信号与 γ-H2AX 阳性细胞数量增加、Rad51 焦点形成减少及其与 γ-H2AX 焦点的共定位有关,从而揭示了不成功的 DDR 事件。这也与在用 Akt 抑制剂处理的 GIST 和 STS 细胞中,在用 Dox 洗脱后,在 Akt 抑制剂存在下培养时,Dox 处理的 GIST 和 STS 细胞的尾部矩(TM)和橄榄尾部矩(OTM)增加一致。总之,我们的数据表明,抑制 AKT 信号可能通过减弱同源介导的 DNA 修复来增强拓扑异构酶 II 抑制剂对 STS 和 GIST 的细胞毒性作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/439d1e1194eb/ijms-21-08842-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/5a50d9e8424e/ijms-21-08842-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/cc95087e685c/ijms-21-08842-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/b6b40bade141/ijms-21-08842-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/cd74c763f6f8/ijms-21-08842-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/53c9fd585d43/ijms-21-08842-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/7c116ce99060/ijms-21-08842-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/57a4c38a9317/ijms-21-08842-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/439d1e1194eb/ijms-21-08842-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/5a50d9e8424e/ijms-21-08842-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/cc95087e685c/ijms-21-08842-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/b6b40bade141/ijms-21-08842-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/cd74c763f6f8/ijms-21-08842-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/53c9fd585d43/ijms-21-08842-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/7c116ce99060/ijms-21-08842-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/57a4c38a9317/ijms-21-08842-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50f2/7700672/439d1e1194eb/ijms-21-08842-g008.jpg

相似文献

1
Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair.抑制 AKT 信号通路通过同源介导的 DNA 修复靶向作用使软组织肉瘤(STS)和胃肠道间质瘤(GIST)对多柔比星敏感。
Int J Mol Sci. 2020 Nov 22;21(22):8842. doi: 10.3390/ijms21228842.
2
Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.抑制 FGFR2 信号通路可减弱 GIST 同源介导的 DNA 修复,并使其对 DNA 拓扑异构酶 II 抑制剂敏感。
Int J Mol Sci. 2020 Jan 5;21(1):352. doi: 10.3390/ijms21010352.
3
Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.成纤维细胞生长因子受体信号传导的抑制使伊马替尼耐药的胃肠道间质瘤对低剂量拓扑异构酶II抑制剂敏感。
Anticancer Drugs. 2018 Jul;29(6):549-559. doi: 10.1097/CAD.0000000000000637.
4
Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.伊马替尼耐药胃肠道间质瘤中频繁的单等位基因缺失与 PTEN 表达缺陷有关。
Mod Pathol. 2014 Nov;27(11):1510-20. doi: 10.1038/modpathol.2014.53. Epub 2014 Apr 18.
5
Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.靶向抑制 PI3K/Akt/mTOR 信号通路:肉瘤治疗的潜力。
Mini Rev Med Chem. 2024;24(16):1496-1520. doi: 10.2174/0113895575270904231129062137.
6
Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.探索 GIST 中的新型治疗靶点:聚焦于 PI3K/Akt/mTOR 通路。
Curr Oncol Rep. 2013 Aug;15(4):386-95. doi: 10.1007/s11912-013-0316-6.
7
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/AKT/mTOR)抑制与阿霉素联合使用是治疗平滑肌肉瘤的有效疗法。
J Transl Med. 2016 Mar 8;14:67. doi: 10.1186/s12967-016-0814-z.
8
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.联合靶向 AKT 和 mTOR 可协同抑制肝癌细胞的增殖。
Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.
9
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.甲磺酸伊马替尼与AKT抑制剂联合使用在胃肠道间质瘤临床前研究中具有协同作用。
Clin Cancer Res. 2017 Jan 1;23(1):171-180. doi: 10.1158/1078-0432.CCR-16-0529. Epub 2016 Jul 1.
10
PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.PD-1/PD-L1 阻断通过 PI3K/Akt/mTOR 信号通路挽救胃肠道间质瘤中耗竭的 CD8+ T 细胞。
Cell Prolif. 2019 May;52(3):e12571. doi: 10.1111/cpr.12571. Epub 2019 Feb 3.

引用本文的文献

1
Single protein encapsulated SN38 for tumor-targeting treatment.载单蛋白 SN38 的肿瘤靶向治疗。
J Transl Med. 2023 Dec 10;21(1):897. doi: 10.1186/s12967-023-04778-0.
2
Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach.抑制 DNA 修复酶:一种有价值的药物研发途径
Int J Mol Sci. 2023 Apr 27;24(9):7954. doi: 10.3390/ijms24097954.
3
The Impact of Oxidative Stress and AKT Pathway on Cancer Cell Functions and Its Application to Natural Products.氧化应激和AKT信号通路对癌细胞功能的影响及其在天然产物中的应用

本文引用的文献

1
Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells.埃博霉素联合 AKT 抑制剂在软组织肉瘤细胞中产生协同细胞毒性。
Sci Rep. 2019 Apr 8;9(1):5759. doi: 10.1038/s41598-019-42300-z.
2
Restraining Akt1 Phosphorylation Attenuates the Repair of Radiation-Induced DNA Double-Strand Breaks and Reduces the Survival of Irradiated Cancer Cells.抑制 Akt1 磷酸化可减弱辐射诱导的 DNA 双链断裂的修复并降低受照射癌细胞的存活率。
Int J Mol Sci. 2018 Jul 31;19(8):2233. doi: 10.3390/ijms19082233.
3
A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Antioxidants (Basel). 2022 Sep 19;11(9):1845. doi: 10.3390/antiox11091845.
4
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors.Akt1 信号过度活跃会增加胚胎性横纹肌肉瘤 RD 细胞系的肿瘤进展和 DNA 修复,并使其易受糖酵解和甲羟戊酸途径抑制剂的影响。
Cells. 2022 Sep 14;11(18):2859. doi: 10.3390/cells11182859.
5
RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair.RAD21通过DNA损伤修复导致预后不良并影响卵巢癌对聚(ADP - 核糖)聚合酶抑制剂的敏感性。
Front Oncol. 2022 Jul 4;12:936550. doi: 10.3389/fonc.2022.936550. eCollection 2022.
6
Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor.联合抑制AKT和KIT可恢复胃肠道间质瘤中程序性细胞死亡4(PDCD4)的表达。
Cancers (Basel). 2021 Jul 23;13(15):3699. doi: 10.3390/cancers13153699.
7
NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway.NTNG1通过GAS6/AXL/Akt信号通路调节上皮性卵巢癌细胞对顺铂的耐药性。
Front Cell Dev Biol. 2021 Jul 1;9:652325. doi: 10.3389/fcell.2021.652325. eCollection 2021.
新型受体酪氨酸激酶开关促进胃肠道间质瘤耐药性。
Molecules. 2017 Dec 5;22(12):2152. doi: 10.3390/molecules22122152.
4
Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner.Akt1 通过依赖 Rad51 的方式刺激 DNA 双链断裂的同源重组修复。
Int J Mol Sci. 2017 Nov 20;18(11):2473. doi: 10.3390/ijms18112473.
5
Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells.Akt1和Akt3而非Akt2通过与DNA-PKcs相互作用,刺激K-RAS突变癌细胞的增殖和辐射后细胞存活。
Cell Death Discov. 2017 Oct 30;3:17072. doi: 10.1038/cddiscovery.2017.72. eCollection 2017.
6
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.甲磺酸伊马替尼与AKT抑制剂联合使用在胃肠道间质瘤临床前研究中具有协同作用。
Clin Cancer Res. 2017 Jan 1;23(1):171-180. doi: 10.1158/1078-0432.CCR-16-0529. Epub 2016 Jul 1.
7
Down-Regulation of AKT Signalling by Ursolic Acid Induces Intrinsic Apoptosis and Sensitization to Doxorubicin in Soft Tissue Sarcoma.熊果酸对AKT信号通路的下调诱导软组织肉瘤的内源性凋亡并增强对多柔比星的敏感性。
PLoS One. 2016 May 24;11(5):e0155946. doi: 10.1371/journal.pone.0155946. eCollection 2016.
8
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/AKT/mTOR)抑制与阿霉素联合使用是治疗平滑肌肉瘤的有效疗法。
J Transl Med. 2016 Mar 8;14:67. doi: 10.1186/s12967-016-0814-z.
9
Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.使用相互作用效力模型在复杂剂量反应格局中寻找药物协同作用
Comput Struct Biotechnol J. 2015 Sep 25;13:504-13. doi: 10.1016/j.csbj.2015.09.001. eCollection 2015.
10
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.吉西他滨、多西他赛联合贝伐单抗治疗软组织肉瘤的II期试验
Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14.